p.104 抽出テキスト

Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 September 25, 2018 e375 CLINICAL STATEMENTS AND GUIDELINES

S7.9.1.1-13.	 Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using videoassisted thoracic surgery. Heart Rhythm. 2009;6:752–9. S7.9.1.1-14.	 Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with lifethreatening ventricular arrhythmias. J Thorac Cardiovasc Surg. 2014;147:404–9. S7.9.1.1-15.	 Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome. Clin Res Cardiol. 2013;102:33–42. S7.9.1.1-16.	 Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826–33. S7.9.1.1-17.	 Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6–15. S7.9.1.1-18.	 Costa J, Lopes CM, Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm. 2012;9:892–8. S7.9.1.1-19.	 Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm. 2010;7:1797–805. S7.9.1.1-20.	 Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and genderspecific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm. 2011;8:1537–43. S7.9.1.1-21.	 Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol. 2006;47:764–8. S7.9.1.1-22.	 Adler A, van der Werf C, Postema PG, et al. The phenomenon of “QT stunning”: The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9:901–8. S7.9.1.1-23.	 Aziz PF, Wieand TS, Ganley J, et al. Genotype- and mutation site-specific QT adaptation during exercise, recovery, and postural changes in children with long-QT syndrome. Circ Arrhythm Electrophysiol. 2011;4:867–73. S7.9.1.1-24.	 Chattha IS, Sy RW, Yee R, et al. Utility of the recovery electrocardiogram after exercise: a novel indicator for the diagnosis and genotyping of long QT syndrome? Heart Rhythm. 2010;7:906–11. S7.9.1.1-25.	 Laksman ZW, Hamilton RM, Chockalingam P, et al. Mutation location effect on severity of phenotype during exercise testing in type 1 long-QT syndrome: impact of transmembrane and C-loop location. J Cardiovasc Electrophysiol. 2013;24:1015–20. S7.9.1.1-26.	 Moltedo JM, Kim JJ, Friedman RA, et al. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. Pediatr Cardiol. 2011;32:63–6. S7.9.1.1-27.	 Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187–94. S7.9.1.1-28.	 Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J. 2004;25:1405–11. S7.9.1.1-29.	 Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955–61. S7.9.1.1-30.	 Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341–4. S7.9.1.1-31.	 Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51–9. S7.9.1.1-32.	 Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149–54. S7.9.1.1-33.	 Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760–81. S7.9.1.1-34.	 Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and

therapy for attention deficit/hyperactivity disorder. J Cardiovasc Electrophysiol. 2015;26:1039–44. S7.9.1.1-35.	 Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the

long-QT syndrome. N Engl J Med. 2003;348:1866–74. S7.9.1.1-36.	 Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an international multicenter study. Circulation. 2016;134:872–82. S7.9.1.1-37.	 Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm. 2009;6:113–20. S7.9.1.1-38.	 Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993;87:1866–72. S7.9.1.1-39.	 Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J. 2004;25:437–45. S7.9.1.1-40.	 Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card Electrophysiol. 2016;47:163–70. S7.9.1.1-41.	 Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012;60:2092–9. S7.9.1.1-42.	 Khositseth A, Tester DJ, Will ML, et al. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004;1: 60–4. S7.9.1.1-43.	 Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation. 1998;97:451–6. S7.9.1.1-44.	 Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431–6. S7.9.1.1-45.	 Eldar M, Griffin JC, Van Hare GF, et al. Combined use of betaadrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 1992;20:830–7. S7.9.1.1-46.	 Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. CIRCULATION. 1991;84:1524–9. S7.9.1.1-47.	 Viskin S, Glikson M, Fish R, et al. Rate smoothing with cardiac pacing for preventing torsade de pointes. Am J Cardiol. 2000;86:111k–5k. S7.9.1.1-48.	 Bos JM, Bos KM, Johnson JN, et al. Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonresponders. Circ Arrhythm Electrophysiol. 2013;6:705–11. S7.9.1.1-49.	 Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358:2024–9. S7.9.1.1-50.	 Li J, Liu Y, Yang F, et al. Video-assisted thoracoscopic left cardiac sympathetic denervation: a reliable minimally invasive approach for congenital long-QT syndrome. Ann Thorac Surg. 2008;86:1955–8. S7.9.1.1-51.	 De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation. 2015;131:2185–93. S7.9.1.1-52.	 Li C, Hu D, Shang L, et al. Surgical left cardiac sympathetic denervation for long QT syndrome: effects on QT interval and heart rate. Heart Vessels. 2005;20:137–41. S7.9.1.1-53.	 Burns C, Ingles J, Davis AM, et al. Clinical and genetic features of Australian families with long QT syndrome: a registry–based study. J Arrhythm. 2016;32:456–61. S7.9.1.1-54.	 Barsheshet A, Goldenberg I, Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125:1988–96. S7.9.1.1-55.	 Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366–75. S7.9.1.1-56.	 Zhang C, Kutyifa V, McNitt S, et al. Identification of low-risk adult congenital LQTS patients. J Cardiovasc Electrophysiol. 2015;26:853–8. S7.9.1.1-57.	 Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharma-

cological treatment. J Am Coll Cardiol. 2004;43:1494–9.

Downloaded from http://ahajournals.org by on October 7, 2026